Reported Outcomes in Major Cardiovascular Clinical Trials Funded by For-Profit and Not-for-Profit Organizations: 2000–2005

2007 ◽  
Vol 2007 ◽  
pp. 391-392
Author(s):  
W.H. Frishman
Keyword(s):  
Clinical Trials ◽  
For Profit ◽  
Not For Profit ◽  
Not For Profit Organizations ◽  
For Profit Organizations

Partnership agreements for regenerative medicines: a database analysis and implications for future innovation

2021 ◽  
Author(s):  
Tingting Qiu ◽  
Yitong Wang ◽  
Shuyao Liang ◽  
Ru Han ◽  
Mondher Toumi
Keyword(s):  
Scientific Discovery ◽  
Biotechnology Company ◽  
Database Analysis ◽  
For Profit ◽  
Preclinical Phase ◽  
Not For Profit ◽  
Licensing Agreements ◽  
Regenerative Medicines ◽  
Not For Profit Organizations ◽  
For Profit Organizations

Aim: Partnerships have been leveraged to advance the regenerative medicines (RMs) development. This study analyzed the evolution of partnership landscape for regenerative medicines (RMs). Methods: Partnership agreements publicly announced from January 2014 – June 2020 were described. Results: 1169 partnership agreements with total amount of US$63,496 million were identified. Most agreements concerned RMs that were for oncology (25.3%), in the discovery or preclinical phase (66.9%) and gene-based products (45.3%). The most common partnership type is collaborative agreements without licensing. The partnerships between ‘Biotechnology company and not-for-profit organizations’ represented the largest number (n = 416; 35.6%). ‘Big Pharma’ preferred collaboration and licensing agreements with a higher amount. Conclusion: Collaborations between highly specialized players with complementary expertise promote the successful translation of scientific discovery to RMs.

Sign in / Sign up

Export Citation Format

Share Document